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Abstract 
Background 
Diverse varieties of often heterogenous glycans are ubiquitous in Nature. They play critical roles in 
recognition events, act as energy stores and provide structural stability at both molecular and cellular 
levels. Technologies capable of fully elucidating the structures of glycans are far behind the other „-
omic‟ fields. Liquid chromatography (LC) and mass spectrometry (MS) are currently the most useful 
techniques for high-throughput analysis of glycans. However, these techniques do not provide full 
unambiguous structural information and instead the gap in full sequence assignment is frequently 
filled by a priori knowledge of the biosynthetic pathways and the assumption that these pathways are 
highly conserved.  
Scope of the review 
This comprehensive review details the rise of the emerging analytical technique ion mobility 
spectrometry (IMS) (coupled to MS) to facilitate the determination of three-dimensional shape: the 
separation and characterization of isobaric glycans, glyco(peptides/proteins), glycolipids, 
glycosaminoglycans and other polysaccharides; localization of sites of glycosylation; or interpretation 
of the conformational change to proteins upon glycan binding.  
Major conclusions 
IMS is a highly promising new analytical route, able to provide rapid isomeric separation (ms 
timescale) of either precursor or product ions facilitating MS characterization. This additional 
separation also enables the deconvolution of carbohydrate MS(/MS) information from contaminating 
ions, improving sensitivity and reducing chemical noise. Derivation of collision cross sections (CCS) 
from IM-MS(/MS) data and subsequent calculations validate putative structures of carbohydrates 
from ab initio derived candidates. IM-MS has demonstrated that amounts of specific glycan isomers 
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vary between disease states, which would be challenging to detect using standard analytical 
approaches. 
General significance 
IM-MS is a promising technique that fills an important gap within the Glycomics toolbox, namely 
identifying and differentiating the three-dimensional structure of chemically similar carbohydrates 
and glycoconjugates. 
 
1. Introduction 
Glycans and their conjugates (proteins, lipids, various anabolites) are found attached to the 
surface of cells, within cells and in the extracellular matrix. They are integral to an extraordinarily 
diverse range of biological processes including regulation of cell-cell recognition
[1]
, cell adhesion
[2]
 
(including host-pathogen interactions
[3]
), immune response,
[4]
 fertilization,
[3a, 5]
 trafficking, and intra- 
and extracellular signalling events. Even subtle changes in carbohydrate structure can result in vastly 
different interactions, make them susceptible to enzymatic hydrolysis or alter glycoconjugate tertiary 
structures and thus affect their observed biological response.
[2a, 6]
 Interestingly both the identity and 
levels (or presence) of specific glycan structures within individuals depends on numerous factors 
including gender,
[5a, 7]
 blood group,
[8]
 age,
[9]
 disease state
[6b, 6g, 10]
 and diet.
[11]
 It remains unclear a 
priori how changes in glycan structure will affect the resultant biological function.
[12]
 Given their 
ubiquity in nature, it is unsurprising that aberrant glycan structures have been identified as biomarkers 
for several disease states including various cancers,
[6a, 6d, 10c, 13]
 hereditary disorders,
[6g, 14]
 acute 
pancreatitis,
[10a]
 immune and cardiovascular deficiencies,
[6b, 12, 15]
 Alzheimer‟s disease[16] and muscular 
dystrophy
[2a]
.  
The incredible amount of three dimensional stereochemical information contained within 
glycans is biologically very important, as it is required to accommodate for their diverse 
functionalities even from a relatively small pool of monosaccharide building blocks. This complex 
„chemical information‟ arises from: (1) different monosaccharide building blocks; (2) the potential to 
link these monomers at a number of different positions in two different stereochemistries, namely α- 
and β-, forming both linear and branched structures; (3) the ability for identical monosaccharides to 
have been incorporated with different ring connectivities, i.e. pyranose and furanose structures (4) 
further decoration with chemically diverse functional groups (e.g. phosphate, sulphate, methyl groups) 
(Figure 1). To understand and exploit glycan-driven functions, it is necessary to be able to 
unambiguously elucidate carbohydrate structures, in the absence of a priori information to be able to 
define structure-function relationships.  To develop and exploit differences in glycan structures as 
potential biomarkers of disease, it will be necessary to define these structures in a high throughput 
manner to allow characterization on a person-to-person basis, permitting the development of novel 
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therapeutics or diagnostics.
[17]
 The demand for three-dimensional structure determination has resulted 
in fewer advances in comprehensive structural elucidation of glycans compared with proteins and 
nucleic acids, especially since glycan structures are not directly encoded by genetic information. 
Moreover, microheterogeneity, the low amounts available for analysis, and the chemical similarity 
between monosaccharide building blocks, which are often simple epimers of one another, hinder their 
full structural elucidation.  
4 
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Figure 1 – Scheme depicting the various types of isomerism routinely observed in nature. The left side of the panel 
highlights the types of isomerism observed and the right side displays naturally occurring examples. Different 
stereochemistries associated with the monosaccharide building blocks (a) Regioisomers of glycosidic bond formation 
between two monosaccharide building blocks, which includes the potential formation of branched structures; (b) 
Positional isomers resulting from addition of a monosaccharide unit to different branching arms; (c) Anomeric 
glycosidic bond isomers α- and β-; (d) Finally, ring size isomers pyranose, p, and furanose, f, (e). 
The current „gold standard‟ for glycan analysis typically involves liquid chromatography (LC) 
separation,
[6a, 6b, 12, 18]
 which can also be coupled with the speed and sensitivity of tandem mass 
spectrometry (MS
2
) (Figure 2).
[19]
 Glycans are then characterized based on either their retention time 
against a standard and/or by their MS
2
 spectrum.
[18b, 20]
 However, LC separation can require multiple 
different columns to gain significant separation of chemically similar glycan species and as a result it 
is often low throughput. Also, without the benefit of (synthetic) reference standards, LC provides no 
structural de novo information. MS alone is limited to characterising the monosaccharide class (i.e. 
hexose, N-acetylhexosamine, deoxy hexose etc.) and is insufficient to directly identify these 
monosaccharide units from each other without the use of an orthogonal sequencing approach. Given 
the intrinsic ability of carbohydrates to be isomeric, these strategies only often work for systems 
whose biosynthetic pathways are well understood (e.g. N-glycans) to facilitate in their identification. 
The inability of this analysis strategy to separate and characterize these iso(mer/bar)ic species from 
complex biological mixtures can hinder the development of specific glycomic approaches for 
assessing disease state.
[10d]
  
 
Figure 2 - Scheme depicting Domon-Costello nomenclature for carbohydrate product ions formed as a result of 
tandem mass spectrometry. Red and blue ions correspond to those formed as a result of fragmenting the glycosidic 
bond and the monosaccharide ring respectively.[21] 
Recently there has been a surge in the application of Ion Mobility-Mass Spectrometry (IM-
MS) to enhance structural characterization and separation of glycans and glycoconjugates. Ion 
mobility spectrometry (IMS) is an analytical technique that measures the mobility, K, of gas-phase 
ions under the influence of an electric field in the presence of a buffer gas; the mobility is based on 
the size, shape and charge of the ions,
[22]
 analogous to electrophoresis in the condensed phase, 
although the timescale is much shorter (high-s to ms). Ions can be generated by a range of 
techniques, although for most IMS applications, ions are generated by ESI. This technique has been 
used for a variety of types of analyses, and has major applications in security and defence for example 
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in airports where it is routinely used to screen against explosives, chemical-warfare agents and drugs. 
The recent surge in use of ion mobility to analyse glycans is primarily as a result of the 
commercialization of hybrid IM-MS instrumentation (Synapt HDMS, 2006) and its potential to 
overcome challenges associated with analysis of glycans; namely separation of often isomeric 
carbohydrates and structural characterization of carbohydrates in conjugation with molecular 
dynamics (MD) simulations.  
This review assesses the applicability of IM-MS towards biologically relevant glycans and 
the wealth of additional information that can be obtained from this high-throughput strategy. This will 
undoubtedly improve our understanding of glycan functions and thus could provide promising tools 
for further medicinal applications. Initially, the various IMS strategies routinely coupled to MS will be 
briefly discussed to help the reader appreciate the limitations and advantages of each of the techniques; 
however for a more thorough background into IMS the reader is encouraged to read excellent previous 
reviews.
[22b, 23]
 Similarly, computational aspects (such as MD simulations) that facilitate elucidation of 
gas-phase structures are briefly discussed, however, they are more extensively detailed elsewhere.
[24]
  
 
2. Ion mobility spectrometry 
 
A number of unique ion mobility analysers have been coupled to MS, each with their own 
benefits and limitations (Figure 3). Each of these analysers are discussed in further detail. 
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Figure 3 – Four different mobility cells for drift tube (a), travelling-wave (b), (high) field asymmetric (c) and trapped 
(d) ion mobility spectrometry. Ions of increasing collision cross section ()-to-charge ratio are depicted as red, blue 
and green spheres. Solid black and green arrows correspond to where the ions enter and exit respectively.  
 
2.1 Drift tube (DT)IMS 
DTIMS is conceptually the simplest form of IMS. Ions are introduced (gated) into a cell 
consisting of a series of stacked electrodes filled with a static drift/buffer gas. A weak, uniform 
electric field (~5-15 V/cm) is applied across the cell causing the ion packet to move through the cell. 
Ions with larger rotationally averaged collision cross section (CCS) undergo more collision/interaction 
events with the drift/buffer gas and as a result take longer to traverse the cell. This CCS represents the 
effective area of the gas-phase ion, under the precise set of experimental conditions that can interact 
with the drift gas, averaged over all orientations and thus can be related to structural or 
conformational features. Mobility separated ions are then separated by their m/z using a mass analyser 
that tends to be, but not exclusively, a time-of-flight device before being detected. The mobility or 
reduced mobility, K0, for a standard set of conditions can then be calculated for the ions using 
equations 1 and 2: 
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Where L is the length of the drift cell, td is the drift time, E is the electric field, P is the pressure within 
the cell and T is the temperature of the buffer gas within the cell. K0 can then be equated to the 
rotationally averaged CCS under a specific set of instrument conditions, , according to the Mason-
Schamp equation (3):
[25]
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Where kb is the Boltzmann constant, mI is the mass of the ion, mB is the mass of the buffer gas, z is the 
charge state, e is the elementary charge, and N is the number density of the drift gas; this relationship 
only holds true for low E/N (<2 Td).
[26]
 
[27]
 At high E/N the electric field causes ion heating and 
therefore a non-linear relationship between 1/K0 and . 
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Figure 4 – Schematic of the commercialially available Agilent DTIMS instrument. 
The resolving power of IMS instrumentation is highly dependent on the choice of buffer gas. 
Classically for gas-phase structural (and separation) analysis, the buffer gas is an inert gas such as 
helium or nitrogen; these two gases have been extensively studied and permit determination of the 
CCS of ions of interest. In the past, other gases have been shown to offer superior separation 
capabilities, particularly gases that are polarizable (i.e. CO2, SF6 and N2O). These gases allow for the 
improved separation of isomeric species, but this separation is highly dependent on the physical 
properties of the analyte.
[25b]
 The resolving power of modern IMS instruments tends to be in the order 
of 50-100 (/) and the increase in resolution tends to come at the expense of sensitivity. One 
major disadvantage of DTIMS is its low duty cycle. The DTIMS instrument has only been used by a 
handful of specialized research groups due to the lack of commercially available instrumentation, 
however, with the recent release of a commercial instrument (Agilent 6560 Ion Mobility Q-
TOF;Figure 4), adoption of DTIMS and its application is expected to rise.
[28]
  
 
2.2 Travelling wave (TW)IMS  
TWIMS was first commercialized by the release of the Synapt HDMS (2006, Waters;Figure 
5).
[29]
 Since then several new improved iterations of the Synapt HDMS series and other 
instrumentation possessing TWIMS (i.e. Waters, Vion IMS QToF) have been released.
[30]
 Ions are 
guided through the mobility cell using a series of ring electrodes (stacked ring ion guide), in the 
presence of a static buffer gas (commonly N2) akin to DTIMS. Travelling waves are generated by 
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raising the voltage on selected, periodically spaced electrodes and then moving the potential along the 
ring electrodes. Ions with smaller CCS undergo fewer collisions with the drift gas and „surf‟ the 
waves, whereas larger ions undergo more collisions and are more likely to tumble over the back of the 
waves. Simultaneously a RF potential is applied to the electrodes creating a well at the centre of the 
cell, radially confining ions and preventing them from diffusing to the electrodes where they would 
annihilate. Mobility separation can be tuned by altering the wave height, velocity or the pressure of 
the mobility cell. Like DTIMS, TWIMS operates in the low E/N regime meaning CCS can be derived.  
However, ion trajectories through the mobility cell have not been fully elucidated and as a result the 
CCS cannot be directly measured from the drift time of the analyte. As a result, CCS derivation by 
TWIMS is achieved by calibration against a series of molecules whose CCS are known and ideally 
are of similar „class‟ to the analyte being studied.[31] When multiple charge states are present in either 
the calibrant or analyte, their CCS is often reported as a mass and charge state normalized value (’) 
calculated using the following equation (4): 
 
                                                                        
    ⁄
 
     (4) 
 
where  is the reduced mass. However, using ’ values for calibration have been reported to 
introduce significant errors.
[31a]
 Unfortunately for structural applications, TWIMS data is commonly 
recorded in nitrogen and DTIMS in helium. TWIMS cannot operate with (pure) helium as a drift gas 
since the cell operates at a potential and pressure beyond the electrical breakdown limit of helium. As 
a result
 TW
CCSN2 is often converted to a representative 
TW
CCSHe
 
value for calibration purposes, 
although this is also reported to introduce error.
[31b, 32]
 The T-wave cell is also reported to produce 
significant ion heating, raising questions on the ability of the instrument to yield structural data 
representative of the solution phase (“native”). However, recent advances of the instrument design 
have been demonstrated to significantly reduce ion heating, with evidence that solution-phase protein, 
peptide and glycan conformers can be retained in the gas-phase.
[33]
  Despite these concerns, the ion 
heating is insufficient to break the covalent bonds, therefore TWIMS is a suitable technique for 
structural analysis of carbohydrates.  
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Figure 5 – Schematic of the Synapt G2-Si (a) and Vion (b) TWIMS mass spectrometers commercialized by Waters. 
The resolving power of TWIMS (~40) is worse when compared to typical DTIMS analysers, 
however its duty cycle and sensitivity are much greater. Another convenient facet of the Synapt 
instrument series is the presence of collision cells before and after the mobility cell (denoted TRAP 
and TRANSFER, respectively), enabling mobility separation of either precursor or product ions.   
 
2.3 (High-)Field asymmetric (FA)IMS 
FAIMS or differential ion mobility spectrometry, unlike DTIMS and TWIMS, operates at 
high field (high E/N, >30 Td
[34]
) and therefore CCS cannot be derived from the mobility data. As a 
result, FAIMS is always used as a gas-phase separation technique at the front-end of the mass 
spectrometer. FAIMS achieves ion separation based on the differential mobility operating in low field 
and high field conditions. Ions are carried by a drift gas between two parallel plates; one plate is held 
at ground whilst an asymmetric waveform is applied to the other. This waveform consists of a high 
potential (high-field) for a short time period followed by application of a low potential of opposing 
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polarity for a longer period of time. These time periods and potentials are designed so that (Vhth) + 
(Vltl) = 0 where Vh and Vl are the voltages applied during the high-field and low-field period 
respectively, and th and tl are the time periods for the high-field and low-field portions of the 
waveform respectively. This ensures that mobility separation is resulting solely from the difference in 
mobility at high- and low-fields.
[35]
 A compensation voltage (CV) is applied allowing transmission of 
ions that have been displaced through their differential mobility by a specific amount. As a result, 
FAIMS can operate as an ion mobility filter akin to quadrupoles acting as m/z filters. In this mode the 
sensitivity is much greater (higher duty cycle) as it can separate ion beams rather than ion packets. 
Conversely the compensation voltage can be scanned to allow detection of all ions, although this 
reduces the sensitivity. The other major advantage of this technique is that it currently has one of the 
highest reported resolving powers that has been reported for an IMS device (>500),
[36]
 with resolving 
powers routinely reported to be ~100. Like TWIMS, the drift gas employed in FAIMS separation is 
typically nitrogen to prevent electrical breakdown,
[37]
 however helium or hydrogen can be doped into 
nitrogen, which was reported to improve the resolving power of the instrument.
[36]
  Alternatively, 
chips with narrower channels could allow the use of helium.
[38]
  
 
2.4 Trapped IMS (TIMS) 
The final IMS technique that shall be discussed is the recently developed trapped IMS 
(TIMS). Ions are pulsed (with a deflection plate) into an ion funnel, where they are radially focused 
before entering the IMS region (Figure 6).
[39]
 Ions enter the TIMS region, which consists of a series of 
airtight plates segmented into quadrants, with a flow of drift gas. An axial electric field opposing the 
drift gas flow is applied trapping ions at different regions within the TIMS cell depending on the ions 
/z. Simultaneously, an RF potential is applied to the quadrants, creating a quadrupole field 
perpendicular to the electric field. This quadrupole field restricts ions to the centre of the cell. The 
axial electric field is then steadily reduced eluting species from high to low /z[39a]  meaning TIMS 
can be used as an IMS filter, like FAIMS. Since TIMS operates at the low-field limit, CCS values can 
be extracted from the data (via calibration to known CCS standards),similar to TWIMS. 
Considering its only recent development and commercialization there are still very few publications in 
the area, especially those related to carbohydrate separation. However, TIMS has been reported to 
offer high resolving powers (>250), surpassing that of the other IMS devices (DT- and TW-IMS).
[40]
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Figure 6 – Scheme of the TIMS cell devloped by Bruker that can be coupled onto the front-end of most 
instrumentation. 
 
3. Computational methodologies 
 
IM measurements alone do not directly reveal any structural insights beyond the relative size 
of measured ions and their conformational dynamics under the defined set of experimental conditions 
used. Instead, the CCS of computationally derived structures is compared to the experimental values 
to elucidate structural information. Theoretical CCS of an ensemble of structures that fit within the 
CCS distribution may indeed represent the gas-phase structure of the given analyte, assuming the 
energy of the structure is not unrealistically high. Normally, a set of structures is extracted from the 
conformational search, with particular focus on the more likely, low energy species. The information 
gathered from IM-MS
n
 experiments combined with computational techniques such as ab initio, semi-
empirical or molecular dynamics simulations can offer powerful insights into the physical features of 
the molecules, including their connectivity, relative size and conformational dynamics.
[41]
  
Despite significant progress being made in the field, generation of feasible models is not a trivial task, 
and goes beyond the scope of this review. For large macromolecular species, such as proteins, the 
initial modelled structures are normally taken from X-ray crystallographic databases or NMR atomic 
coordinates, as structure elucidation from primary sequence information alone is extremely difficult.  
  Modelling of smaller molecules, such as glycans, is achievable although computationally 
challenging even for mono- and di-saccharides. As expected, the main difficulty comes from the high 
diversity and flexibility of these species. 
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The CCS values for the generated models are normally based on one of the following theoretical 
methods; Projection Approximation (PA),
[42]
  Exact Hard Sphere Scattering (EHSS),
[45]
 Trajectory 
Method (TM)
[43]
 or the Projection Superposition Approximation (PSA)
[44]
 (Figure 7).
[24b]
 The choice 
of algorithm largely depends upon the physical properties and size of the analyte but also the 
computational resources available. The PA was the first theoretical method used to calculate CCS 
from atomic coordinates. Simplistically, the molecule is held in a fixed position and the atomic 
„shadow‟ it casts onto a 2-dimensional plane is probed with a buffer gas; if the buffer gas was to 
collide with the „shadow‟ the collision is counted as a hit and is  measured. The molecule is randomly 
rotated around its axis, which is repeated multiple times to generate a rotationally averaged shadow or 
projection of the shape of the molecule, and is stopped once defined convergence criteria are met.
[42]
  
The PA method is computationally least demanding, and offers the simplest and quickest 
approximation of the CCS, however, it does not account for the multiple scattering events that might 
occur during the collision and ignores all long-range interactions with the buffer gas.  Slightly more 
sophisticated of the theoretical methods is the EHSS which treats molecules and the drift gas as rigid 
hard spheres, with pre-determined radii. Unlike PA, this method takes into account the multiple 
scattering events, although still does not take into account the interaction potentials of the system with 
the buffer gas. As a result EHSS remains computationally inexpensive, whilst offering better 
approximation.
[45]
 The most commonly used method to study small molecules is the TM, which 
accounts for the long-range interactions during the collisions of the molecule with the buffer gas. The 
TM is typically the most reliable algorithm to theoretically derive CCS, however, it is also the most 
computationally demanding.
[43]
 The TM has been parameterized and evaluated for helium and 
nitrogen, which are typically used in the IMS experiments; the parameters defined in the TM as 
implemented by Mesleh (for helium)
[43]
 and Campuzano (for nitrogen)
[46]
 are limited to several atomic 
types, meaning only certain classes of molecule can be accurately examined. The typical approach to 
overcome this limitation has been to define the parameters for unknown atoms yourself, or replace 
them with similarly sized atoms (compromising the accuracy of the calculated CCS). Finally the PSA, 
which was developed by Bleiholder et al., includes atomic potentials and a shape factor within the 
more simplistic and computationally efficient PA algorithm.
[44]
 This method outperforms the EHSS 
and agrees relatively well with the TM, however is computationally 100-1000 times quicker making it 
an attractive alternative for larger systems such as glycoproteins or polysaccharides.
[44a]
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Figure 7 – Schematic of how the different models calculate CCS. The trajectory model, where the long range 
interactions between the drift gas and analyte ion are taken into account when determining the gas deflection 
trajectories and scattering angles (a). Exact hard sphere scattering model, where atoms within the analyte are 
considered as hard spheres and scattering angles between the drift gas and analyte are calculated (b). Projection 
approximation where the atoms are considered as hard spheres and the projected ‘shadow’ of all possible analyte 
orientations is calculated (c). Finally, the projection superimposition approximation which is similar to the PA, except 
atoms are considered as ‘soft’ spheres, accounting for the collective size effect by superimposition of all atomic 
contributions. The resulting value is scaled by a shape factor to account for molecular cavities (d). Figure taken from 
D’Atri et al.[24b]   
 
4. Application of IMS to analysis of carbohydrates and their conjugates  
 
Broadly speaking, IMS can be applied for two functions: separation of ions and the 
measurement of arrival time distributions (ATDs) and calculation of CCS (structural applications) in 
the hope of defining precise gas-phase structural information from computational studies. However, 
there is currently no specific set of IMS conditions that have been demonstrated to be able to separate 
all carbohydrates or computational methods to generate theoretical structures. As a result, IMS 
separation of derivatized
[47]
 and underivatized carbohydrates have been performed with a plethora of 
different adducts in both positive and negative ion mode.
[48]
 Separation has been achieved with a 
variety of drift gases,
[48b, 49]
 at different temperatures and pressures, on different mobility analysers.
[49a, 
50]
 Samples have also been ionized by different techniques, predominantly MALDI
[48d]
 and 
ESI,
[50b]
with differing sample preparations, all of which will affect the measured ATDs. Improved 
separation has been reported in numerous ways for each IMS device. Changing the drift gas to larger, 
more polarizable molecules such as carbon dioxide has resulted in the ability to baseline separate 
isomers, which were otherwise unresolved.
[48b, 49a, 51]
 Lalli et al. reported for other small molecule 
isomers that increasing the pressure also improves the resolving power (rather than peak-to-peak 
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distance), although massively impacts on the ion transmission (i.e. sensitivity).
[49a]
 Raising the 
temperature of the drift gas is also likely to reduce the resolving power based on theoretical 
calculations, although no systematic study has been attempted for carbohydrates as far as the authors 
are aware.
[52]
 Additionally it is (currently) impossible to discern any structural information from 
computational calculations using polarizable gases as no suitable algorithms have been formulated.
[49a]
 
Alternatively, changing the ions adduct type can result in differential mobilities.
[53]
 These factors have 
allowed the separation α/β-anomers of 1-Me-Glc, 1-Me-Gal and 1-Me-Man.[48b] Recently, Hofmann 
and co-workers reported the greatest separation of anomers and regioisomers as deprotonated adducts 
compared to protonated, sodiated and chloride adducted.
[48a]
 Separation as metal adducts may be more 
challenging as the structures „deform‟ in the gas-phase in order to solvate the charge of the adduct,[54] 
potentially masking isomeric differences in certain cases. Computational studies can also be more 
challenging when using more „exotic‟ adducts (such as heavy metals) for reasons similar to those 
occurring  with different drift gases. Improvements in IMS separation achieved by changing the drift 
gas or adduct are difficult to predict as they depend on the chemical properties of the analyte.
[55]
 In 
fact the choice of adduct is normally dictated either by the analyte, (acidic carbohydrates normally 
deprotonate readily
[56]
 whereas neutral carbohydrates tend to sodiate
[50b]
) or its ability to generate rich, 
structurally informative and diagnostic product ions upon activation of the complex.
[57]
 Applications 
of IMS to facilitate separation and structural characterization of glycans will be discussed in detail for 
the different types of glycans and glycoconjugates. 
 
 
4.1 Free-glycans 
 4.1.1 Mono- to hexa-saccharides 
4.1.1.1 Separation 
Initial application of IMS to carbohydrates focused on whether or not IMS had sufficient 
resolution to distinguish simple (mainly mono-, di- and tri-saccharides) isomeric carbohydrates. Liu et 
al. (1997) first demonstrated that ability of DTIMSN2 to distinguish a small sub-set of isomeric 
precursor and product ions derived from raffinose and melezitose and α-cyclodextrin, β-cyclodextrin 
and γ-cyclodextrin.[58] Using their home-built DTIMSN2 device, the Hill group then demonstrated 
separation of 21 different carbohydrate standards, including a significant number of isomers.
[59]
 The 
same group later reported the ability to separate a substantial number of all known (sodiated) 1-methyl 
hexoses and selected 1-methyl N-acetylhexosamines (GlcNAc and GalNAc) monosaccharides as both 
their α-/β- anomers using both DTIMS and TWIMS. For the most part α- and β- 1-methyl anomers of 
each hexose could be discriminated by both DTIMS and TWIMS other than gulose and certain 
diastereoisomers could also not be separated such as 1-Me-β-allose and 1-Me-β-glucose.[60] As might 
be expected the DTIMS displayed a higher resolving power. Recently, the Pagel and Seeberger 
groups demonstrated the ability of IM-MS to separate and quantify anomers and regioisomers of 
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chemically synthesized tri-/penta-saccharide precursor and product ions down to concentrations as 
low as 0.1% of the dominant anomer glycans (Figure 8).
[48a]
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Figure 8 – ATDs associated with a mixture of two anomeric carbohydrates at ratios defined on each distribution. 
Figure amended from Hofmann 2015.[48a]   
FAIMS has also been demonstrated to be capable of resolving anomeric, linkage and positional 
isomers of a series of chemically synthesized glycosides as a number of different adducts in both 
positive and negative ion mode.
[48c]
 Mobility separated precursors are routinely dissociated by  
collision-induced dissociation (CID) to generate structural information.
[57a, 61]
  
Even with application of IMS, baseline separation of isomeric precursors is often not fully 
achieved. Chimeric ATDs resulting from isomeric precursors can be extracted if a post-mobility 
generated product ion is specific to a given isomer (sometimes termed extracted fragment ion drift 
time distributions or XFIDTDs).
[53, 61e]
 Post-mobility CID enabled elucidation of isomeric glycosides 
within the glycourinome of a patient suffering from symptoms assigned to a congenital disorder of 
glycosylation.
[62]
 This structural variance could have been overlooked by MS alone. Alternatively, the 
mobility of product ions generated from CID of isomeric precursors may be separable.
[53, 61c, 63]
 For 
example Li et al. (2013) measured the ATDs of a series of dihexose anomers, regioisomers and 
diastereoisomers by TWIMS. Despite the fact that certain precursors co-eluted in mobility, their 
respective monosaccharide-glycolaldehyde cross-ring product ions did not.
[63]
 To circumvent the 
possibility of the quadrupole co-selecting isomeric/baric precursors for fragmentation, which would 
result in unwanted chimeric product ion spectra, the same group incorporated a dual gated DTIMS 
device in place of the source region of a Synapt HDMS (commercial TWIMS instrument). This 
allows mobility selection of precursors prior to mass selection, CID and subsequent mobility 
separation of the generated products ions (tandem IMS). This mobility selection was achieved using a 
dual gate drift tube where one gate allows ions to enter the drift cell and the second allows ions to 
leave the cell. The second gate is opened at a defined time after the first allowing only ions of that 
specific mobility to be transferred into the ion trap. However, this gating of ions dramatically reduces 
the duty cycle and by virtue the sensitivity (Figure 9).
[64]
  Further improvements in separation has 
been achieved by combining energy-resolved (ER)-MS with IMS, since diastereomeric glycans may 
dissociate at different energies.
[57b, 65]
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Figure 9 – The tandem IMS instrument developed by the Hill group, formed from connecting a dual gated DTIMS 
onto the source of a TWIMS mass spectrometer (a). Inset are the DT (b) and TW (c) ATDs associated with a mixture 
of Galα-1-4Gal-ol and Glcβ1-6Glc-ol. ATDs of the pure compounds measured by the DT (d) and TW (e) analyser  
confirming that the mixture is separable. (f) and (g) are the tandem mass spectra associated with the mobility selected 
peaks labelled 1 and 2, respectively, within panel (c). Figure amended from Li et al.[64] 
From initial work on simple chemically synthesized standards, isomeric disaccharide-alditols, 
chemically released from the O-linked glycoprotein bovine submaxillary mucin (BSM) by alkaline 
borohydride treatment, have been separated by IMS, which could not be achieved by HPLC alone. 
[61b, 
66]
 Unlike reducing carbohydrates these alditols possess less conformational variability (i.e. narrow 
ATDs consisting of a single peak), which is likely as a result of the inability of non-reducing glycans 
to mutarotate between isomeric structures.
[61a, 61b]
 MS
n
 (multistage tandem mass spectrometry where n 
denotes the number of activation events) of mobility selected HPLC fractionated BSM carbohydrate-
alditols, yielded further diagnostic structural information.
[61a, 61b]
  Anionic carbohydrate alditols were 
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also separable by TWIMS with greater sensitivity, albeit at the loss of some IMS resolving power.
[61c]
 
Post-mobility CID generated diagnostic tandem mass spectra from isomeric precursors. Additionally, 
CID generated BSM carbohydrate-alditol product ions could be separated with and without mass 
isolation. The mobility separated product ions could also be made to dissociate again producing 
further structural information.
[61c]
      
As the reader may have noticed, the vast majority of these strategies exploit CID to fragment 
precursors, principally because it is the simplest method to achieve dissociation. However, other 
informative dissociation methods have also been employed. Lee et al. performed vacuum ultraviolet 
photodissociation (VUVPD) (157 nm) on several mobility-separated isomeric disaccharides, which 
produce similar CID tandem mass spectra.
[57a]
 VUVPD generated significantly more cross-ring 
fragments than CID and their presence was found to be highly dependent on the regiochemistry and 
anomeric configuration of specific precursors. This enabled discrimination and identification of all 
isomers.
[57a]
 Finally Hernandez et al. mobility selected lithiated, sodiated and potassiated α/β-1-methyl 
anomers of Glc and Man by FAIMS.
[61d]
 Mobility selected ions were accumulated in a quadrupole ion 
trap before being irradiated with various wavelengths of infrared radiation. Ions absorb IR radiation 
and dissociate when their structures possess resonant vibrational modes. Therefore plotting the 
fragmentation yield against the wavelength of light, normalized to the respective laser power at each 
frequency, generates an action IR spectrum. From this action IR spectrum, the gas-phase structures of 
each of these complexes were determined in the presence of a single water molecule (Figure 10).
[61d]
 
The combination of IMS, IR and MS is an extremely powerful technique. IMS can separate isomers, 
which would be indistinguishable by MS alone and can provide structural information on the intact 
complex; MS rapidly separates species by their m/z and can generate connectivity information through 
tandem mass spectrometry; IR provides specific atomistic information often lacking from IM-MS 
approaches alone.  
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Figure 10 – [Meα1-Glc+H2O+Li]
+ (green) and [Meα1-Man+H2O+Li]
+ (red) complexes, mobility separated by FAIMS 
(black trace). Species can then be mobility selected prior to variable wavelength action IR MS. MD calculations of 
theoretical structures that would give rise to these traces suggest that the coordination site of Li+ differs between 
Meα1-Glc and Meα1-Man. Figure taken from Hernandez.[61d] 
IMS provides benefits, other than just separating isomeric ions: it can be used to help „filter‟ 
carbohydrate specific data from contaminating ions or other molecular species.
[62]
 This can be easily 
visualized on a plot of m/z vs. drift time/CCS as certain classes of ions tend to run in similar regions 
on this plot. This enables simultaneous analysis of glycans and glycopeptides within the same 
experiment, circumventing laborious sample purification and separation steps and potentially 
facilitating future high-throughput glycoproteomics.
[67]
  Carbohydrates can also be chemically 
derivatized to alter their m/z and CCS, so they appear in an uncongested region within this 2D plot.
[47]
 
 
4.1.1.2 Structural 
As mentioned within the introduction of this section, IMS can provide structural information, 
facilitated by computational calculations. This was first reported by the Bowers group, who measured 
the 
DT
CCSHe of a series of sodiated tetrahexoses and hexoses. The lowest energy conformations of 
these structures were computed and their theoretical CCSHe determined by projection approximation. 
For each carbohydrate, the lowest energy structures had the carbohydrate chain wrapping around the 
sodium ion, forming 4 coordinate bonds to 4 monosaccharide units, solvating the charge. These 
theoretical CCSHe matched well with experimental values suggesting that these were indeed 
reasonable representations of the measured gas-phase structures.(Figure 11)
[54]
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Figure 11 – Scatter plot representing the energy and cross section of MD generated sodiated callotetraose structures. 
The shaded area highlights the experimentally measured DTCCSHe. Structures A, B and C are representative 
structures within areas of the plot, Figure amended from Lee et al.[54] 
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Leavel et al. showed by DTIMS that for a [Zn+diethylenetriamine+hexose+Cl]
+
 complex the 
stereochemistry of the hexose also influences the metal binding site.
[55a]
 A significant number of 
recent papers have employed TWIMS to measure the CCS of carbohydrate ions. As mentioned in 
section 2.2 CCS measurements can only be made on TWIMS instruments by comparing it to a 
calibration curve of standards whose CCS areas had been previously measured on a DTIMS 
instrument. However, care must be taken when choosing appropriate standards as it has been reported 
that calibrating glycan CCS to a peptide calibrant introduces a small but systematic error of ~1%, 
presumably due to differences in the interaction potential between peptides and carbohydrates with 
the drift gas.
[31]
 Similarly, charge state mismatching introduces large errors (~3.5%), i.e. the error 
associated with normalising both mass and charge states within the measured data. Mismatching both 
charge state and the molecular class increases this error further (~4.7%).
[31a]
 Similarly, large errors are 
associated with trying to convert 
DT
CCSHe to 
TW
CCSN2.
[31b]
 Fenn et al. measured the 
DT
CCSHe values 
for over 300 carbohydrates including isomers,
[53]
 and Hofmann et al. measured the 
DT
CCSHe and 
DT
CCSN2 of a dextran polymer
[31b]
, both of which can be used to calibrate TWIMS analysed 
carbohydrates. Pagel et al. also determined the 
DT
CCSHe and 
DT
CCSN2 of N-glycan precursors and 
product ions. Glycans were released with hydrazine from RNase B, fetuin, asialofetuin, ovalbumin, 
porcine thyroglobin and desialylated porcine thyroglobin, which could be beneficial for calibration of 
TWIMS for N-glycan analysis as discussed within the next section.
[68]
 
Huang et al. measured the 
TW
CCSN2 of various di-, tri-, penta- and hexa-saccharides as their 
group I metal adducts (Li
+
, Na
+
, K
+
, Rb
+
, Cs
+
) and noted that the 
TW
CCSN2 generally increased as the 
metal ion radius increased, although in an isomer specific manner, which likely reflects the 
differences in coordination site.
[53, 55b]
 The same group also demonstrated IMS separation of isomeric 
lacto-N-fucopentose I and  lacto-N-fucopentose V, and  lacto-N-difucohexaose I and lacto-N-
difucohexaose II as Ca and Ba radical cation adducts,
[69]
 which have been reported to be difficult to 
separate by both IMS and MS
2
, including as divalent Ca
2+
 and Ba
2+
 adducts.
[53, 55b, 69-70]
 An additional 
benefit was that these radical cations generated much more diagnostic CID product ions compared to 
their divalent equivalent.
[69]
  
Structure determination is not only limited to precursor ions, but also product ions. This is 
exemplified by the work of Both et al. who measured the TWIMS arrival time distributions of a series 
of isomeric hexose and N-acetylhexosamine glycosidic product ions (B-, C-, Z- and Y-) derived from 
CID of either glycopeptides or reducing carbohydrates.
[50b]
 Crucially, the ATDs of these product ions 
were independent of the initial precursor, therefore they were able to „sequence‟ the stereochemistry 
of the monomeric product ions (Figure 12). Incorporation of multistage tandem mass spectrometry 
prior to IMS enabled complete elucidation of the monosaccharide building blocks within Man3 glycan 
and helped reveal promiscuity of the glycosyltransferase pp-GanT2.
[50b]
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Figure 12 - Drift times (in ms) and CCS values (in Å2) in parentheses for selected [M+Na]+ product ions are presented 
below the structures. Terminal monosaccharide and disaccharide product ions could be characterized after a single 
round of CID. Internal residues were characterized following in-source dissociation (ISD), quadrupole mass isolation 
of the desired ISD product ion, and subsequent CID before IM-MS. C1 ions can be grouped either as β-Man (shaded 
dark green) or α-Man (shaded light green). All identified Y1, C2 and Y2 product ions could be characterized as 
GlcNAc (shaded blue), Manβ1-4GlcNAc (shaded red) and GlcNAcβ1-4GlcNAc (shaded purple), respectively. For 
cases where two conformations (potential sites of sodiation) were observed, the drift time and CCS measurements are 
reported for the predominant species. CCS values for the disaccharides were not determined (ND) as the drift time 
values lie outside this calibration range. n/a, not applicable. Figure taken from Both et al.[50b] 
Recently, the Clemmer group measured the 
DT
CCSHe of lithiated precursor and CID generated product 
ions on a home-built tandem DTIMS instrument. Even though specific precursors had identical CCS 
(for example sucrose and leucrose) their product ion CCSs differed (although these product ions may 
have consisted of multiple different species due to the potential existence of isomeric product ions).
[71]
  
  
 4.1.2 N-glycans 
Analysis of structurally larger and more complicated N-glycans largely built upon the initial 
studies on smaller glycan standards.
[67-68]
 Fenn et al. and Harvey et al. demonstrated the benefit of the 
additional gas-phase separation afforded by IMS to help characterize N-glycan isomers released from 
the glycoproteins RNase B, gp120 and fetuin, either enzymatically or chemically.
[48d, 56, 67]
 Zhu and co-
workers were able to separate four isomers of permethylated Man7 glycan released from RNase B by 
DTIMS and post-mobility CID. Deconvolution of the ATDs into the four isomers was facilitated by 
extracting the ATDs associated to isomer specific fragment ions.
[61e]
 Like for small molecules, N-
glycans can also be readily separated from contaminating species.
 [56, 72]
  For example N-glycans have 
been profiled directly following PNGase F release in the presence of salt and detergents. This 
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minimizes sample loss from purification strategies or liquid handling steps and additionally reduces 
the experiment time.
[56, 72b]
 Glycosides can also be readily deconvoluted into classes from the m/z vs. 
drift time 2D plots (Figure 13), for example singly, doubly and triply charged glycans and 
glycopeptides. These species would be unidentifiable based on the signal-to-noise of the MS 
acquisition alone.
[56]
 Glycans and glycopeptides could also be fractionated by LC prior to IMS to 
improve separation and the detection capacity.
[72a]
  
 
Figure 13 – 2D plot of the drift time against m/z (log intensity scale) of the negative charged ions generated from ESI 
of N-glycosides released from bovine fetuin by hydrazinolysis (a). The total mass spectrum (b) and the extracted mass 
spectra of the regions (c-j) within the 2D plot. Figure taken from Harvey et al. with permission.[56] 
With the additional orthogonal separation afforded by IMS, Isailovic et al. demonstrated 
profiling of total human serum glycans from patients suffering from liver cancer or cirrhosis of the 
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liver.
[10c]
 Differences in the ATDs associated to specific permethylated N-glycan precursor ions, likely 
result from changes in the isomeric distribution of that given ion. In some cases, variance in the ATDs 
of certain glycan ions between individuals could be separated into healthy and diseased cohorts after 
principle component analysis (PCA).
[10c]
 This data suggests that aberrations in isomer distributions 
may be indicative of disease states. Considering ATDs associated with multiple different isomeric 
glycans improved the reliability of the PCA to cluster 81 individual samples into specific disease (and 
apparently healthy) cohorts significantly (Figure 14),
[10d]
 whereas MS alone did not demonstrate any 
significant clustering. Using the same strategy, Gaye and co-workers were able to characterize serum 
N-glycans into cohorts derived from three disease phenotypes namely Barrett‟s esophagus, high-grade 
dysplasia and esophageal adenocarcinoma, from normal controls of apparently healthy individuals.
[10e]
 
Interestingly, a significant number of glycans selected for PCA within this experiment were identical 
to those selected for the liver disease state experiments.
[10e]
 
 
Figure 14 – Supervized PCA of drift time profiles of 10 unique m/z glycan ions namely Fuc1Hex5HexNAc4
3+, 
Neu5Ac1Hex5HexNAc4
2+, Neu5Ac1Hex5HexNAc4
3+, Neu5Ac1Fuc1Hex5HexNAc4
3+, Neu5Ac2Hex5HexNAc4
2+, 
Neu5Ac2Hex5HexNAc4
3+, Neu5Ac2Hex6HexNAc5
3+, Neu5Ac3Hex6HexNAc5
3+, Neu5Ac3Fuc1Hex6HexNAc5
3+, and 
Hex5HexNAc2
2+. Taken from Isailovic et al.[10d]  
Given the increased structural complexity associated with N-glycans compared to the smaller 
glycosides, few papers have been able to deliver structural information from the IMS data. 
Impressively though, Plasencia et al. determined the 
DT
CCSHe for three species associated with the 
disodiated permethylated Hex5HexNAc4 glycan released from ovalbumin (Figure 15). They argue that 
these three species arise from three different isomers of Hex5HexNAc4. CCS calculations (using TM) 
of the 10 lowest energy structures (after sequential simulated annealing) for each potential isomer 
were within 2.2% uncertainty of the experimental data, allowing assignment of each species within 
the ATD for these three isomers.
[73]
 Williams et al. also determined the 
DT
CCSHe and 
TW
CCSN2 for N-
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glycans released from RNase B, ovalbumin and porcine thyroglobin with and without desialylation. 
Using both the EHSS and TM, they determine the CCS of modelled structures, which again match 
well with the experimental data from both DTIMS and TWIMS analysers.
[33c]
 Finally, Struwe et al. 
also measured 
DT
CCSHe, 
DT
CCSN2,
 TW
CCSHe, and 
TW
CCSN2 for a series of N-glycans as protonated, 
deprotonated, sodiated, potassiated, chloride and phosphate adducts. Computational simulations 
suggest that N-glycans wrap around metal adducts to solvate charge, as previously demonstrated by 
the Bowers group for smaller carbohydrates.
[54]
 Also for given carbohydrate ions, multiple 
conformations were observed. These CCS values were stored in a database (Glycomob housed within 
UniCarbKB) as a Glycomics IMS-MS resource.
[74]
 
 
Figure 15 – Calculated cross sections (TM) and energies from MD simulations after simulated annealing for the three 
[H5N4+2Na]
2+ isomers. Experimental CCS for the three isomers are highlighted by the dashed lines. [H5N4a+2Na]
2+, 
[H5N4b+2Na]
2+, and [H5N4c+2Na]
2+ are represented by blue, red and black diamonds respectively. Representative 
low-energy structures for each isomer are shown. Bisecting GlcNAc and the α1-3 mannose arm are shown in green 
for clarity. Figure amended from Plasencia et al.[73] 
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 4.1.3 Glycosaminoglycans (GAGs) and other Polysaccharides 
Glycosaminoglycans (GAGs) are a family of linear anionic polysaccharides found almost 
ubiquitously on animal cell surfaces and within the extracellular matrices. GAGs have several 
biological functions such as cell-cell communication, cell adhesion, modulation of axonal and cell 
growth, proliferation, angiogenesis, anti-coagulation properties, viral invasion, tumor progression and 
metastasis.
[75]
 Furthermore, they are known to bind numerous proteins such as chemokines, cytokines, 
proteases, growth factors, pathogen proteins and adhesion molecules.
[75b, 75c, 76]
 Consequently, GAGs  
have an extensive medical potential application (e.g. heparin for their anticoagulant properties).
[77]
 
Characterization of this family of polysaccharides is therefore fundamental to understand their 
structure/function relationship but represents a challenging task due to their inherent sequence, de-
acetylation and sulfation heterogeneity.
[11b, 75a, 76a, 78]
 Consequently, despite the numerous biological 
activities of GAGs, there are few function specific sequences that have been completely elucidated.
[79]
 
It is also known that modification of the GAG affects its conformation and as a result influences its 
ability to bind certain proteins such as the fibroblast growth factor-2 or antithrombin that are involved 
in the blood-coagulation cascade.
[80]
 IMS offers the ability to monitor potential dynamic 
conformational changes upon varying the GAG sequence identity. Jin at al. performed conformational 
analysis of fully or partially sulfated heparin-derived di- and tetra-saccharides using a combination of 
DTIMS-MS and molecular modelling (using PA model) of 
DT
CCSHe.
[33e]
 The authors demonstrated 
that even minor changes to the primary structure of the GAG saccharides, for example changing the 
position of one sulfate or epimerization of an IdoA residue to GlcA, led to significant changes in 
conformation. Computational models supported the experimental results, and suggested that sodium 
adducts localized towards negatively charged groups and thus play an important role in conformation 
stabilization and the observed oligomerization of disaccharide units.
[33e]
 The heparin-derived 
tetrasaccharides wrap around the sodium cations, presumably to solvate charge, forming compact 
structures.
[54]
 More recently, Leary et al. explored the affect various alkali metal (Na
+
, K
+
), alkaline 
earth metal (Mg
2+
, Ca
2+
) and transition metal (Mn
2+
, Co
2+
, Fe
2+
, Ni
2+
) adducts had upon the 
conformation of a heparin octasaccharide,
[81]
 since it has been previously demonstrated that these 
cations have influenced several protein-heparin interactions.
[82]
 In all cases, increased affinity resulted 
in contraction of the heparin structure. However, conformational changes upon successive addition of 
metal cations depended on the identity of the metal adduct, which probably results from differing 
atomic radii and valences (Figure 16). In particular, the Ca
2+
 ion induced significant conformational 
contraction. Importantly, similar conformational changes were observed in solution to the gas phase 
IM-MS experiments, illustrating the relevance of the IMS techniques to investigate the 
structure/function relationship of GAGs.
[81]
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Figure 16 - The difference in arrival time distributions between metal and metal free coordinated heparin 
octasaccharide, plotted against the number of metal adducts (a) in the 5− charge state and (b) in the 4− charge state. 
Differences in ATDs are calculated by subtracting the ATDs for metal coordinated octasaccharides from those of the 
metal free species. ATDs of calcium and potassium coordinated octasaccharides that exhibit two ion populations in 
the ion mobility spectrum are shown with the most abundant ion population represented. Figure taken from Seo et 
al.[81] 
 
Along with monitoring the conformational dynamics of GAGs, IMS has been used to separate 
isomeric species. The Leary group have reported applications of TWIMS-MS
2
 for the separation and 
the sequencing of two heparan sulfate (HS) isomers, facilitated by 
1
H NMR.
[83]
 Two isomeric HS 
hexasaccharides, purified by size exclusion and strong anion-exchanged chromatography, both 
produced highly similar mass spectra and enzymatic digestion profiles. TWIMS separation and 
subsequent CID of mobility separated ions was able to distinguish these epimeric hexasaccharides, 
which differed only by the stereochemistry at a single position (GlcA vs IdoA). Miller et al. also 
demonstrated TWIMS separation and identification of six tagged DP 8(degree of polymerization) 
heparan sulfate isomers differing only by their presence and absence of IdoA and GlcA at the 
hexuronic positions.
[84]
 Fully IdoA DP8 structures displayed a more extended and flexible 
conformational distribution compared to the fully GlcA octasaccharide. The authors suggest this is 
because GlcA is reported to preferentially adopt the rigid 
4
C1 chair conformation, whilst IdoA adopts 
a dynamic mixture of 
1
C4, 
4
C1 and 
2
S0 conformations.
[85]
 Interestingly, changes of IdoA to GlcA and 
vice versa within specific locations along the DP8 chain caused conformational distortions, which 
could be separated by TWIMS (Figure 17). 
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Figure 17 – Arrival time distributions and TWCCSN2 associated with six DP8 hexuronic acid positional isomers. 
Amended from Miller et al.[84]  
The intensity distribution of specific fragments differed when GlcA or IdoA was adjacent to the 
glycosidic bond cleavage site (more facile for GlcA) allowing unambiguous elucidation of the 
hexuronic acid sequence. Another report described the ability of IM-MS
2
 to separate three synthetic 
heparin octasaccharides differing in sulfation or acetylation patterns employing a similar strategy.
[86]
 
Two arrival time populations were observed for certain oligosaccharides, suggesting the existence of 
two distinct conformations bearing the same sulfation pattern. Indeed, the presence of sulfation at the 
2-OH position of iduronic acid residues has been reported to lead to a mixture of conformers, 
corresponding to either a chair 
1
C4 or/and a skew 
2
S0 conformation.
[87]
 Recently, Lemr and co-workers 
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reported the use of TWIMS combined with MS
2
 in order to separate hyaluronic acid isomers as well 
as to determine both their structural composition and their isomeric ratio.
[88]
 While IMS allowed 
separation of tyramine positional isomers, subsequent CID fragmentation of separated precursor ions 
led to similar mass fragments often with only differing intensities, making structural characterization 
challenging. To overcome this limitation, the reducing end of the GAG isomers were reductively 
labelled by NaBH4 or stable isotope NABD4 (both performed in H2O), which increased the mass by 2 
or 3 m/z respectively. This chemical modification resulted in the production of characteristic MS/MS 
fragments for each positional isomer and thus allowed their unambiguous identification and 
quantification even from mixtures.  
Recently, Kailemia et al. have reported the first application of FAIMS, combined with Fourier 
transform ion cyclotron resonance mass spectrometry (FTICR-MS) and electron detachment 
dissociation (EDD) tandem MS, to mobility separate, select and characterize both anomeric and 
isobaric GAGs.
[89]
 A chondroitin sulfate A (CSA) mixture of oligomers at various degrees of 
polymerization (DP4 to DP10), which was prepared by partial enzymatic digestion, produced similar 
MS spectra. FAIMS was able to separate the mixture of oligomers at different degrees of 
polymerization, although each peak was not necessarily baseline resolved. Furthermore, some 
oligomers were observed in more than one peak, which was attributed to the presence of a mixture of 
reducing anomers. Synthetic HS tetramers, whose reducing anomeric alcohol had been methylated, 
locking the anomer as either α- or β-, both produced a single distinguishable ATD under identical 
FAIMS conditions suggesting this hypothesis may be true. Alternatively, chemical reduction of the 
free reducing ends using NaBH4 to a single alditol species produced similar results. Mobility selected 
ions were fragmented by EDD, which is reported to preserve labile sulfate moieties,
[90]
 and m/z of the 
resultant product ions were measured on an FTICR-MS for high mass resolving power. While the 
fragment ions obtained in every sample were similar, different intensities were observed. PCA 
allowed differentiation of each of the stereoisomers.
[89]
 
  Biologically relevant polysaccharides other than GAGs have also been studied by IMS to help 
separate isomers or monitor conformational variability. Rashid et al. have reported the discrimination 
of isobaric linear -glucans with a DP of up to 35 using TWIMS in negative ion mode.[33d] Several 
singly charged 1-4-linked maltooligosaccharides and α1-6-linked dextrans, with DP comprised 
between 2 and 10, were distinguishable by their 
TW
CCSN2. Similarly, doubly charged and triply 
charged equivalents of the species between DP 3-24 and 14-35 respectively, were also distinguishable 
(Figure 18).  
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Figure 18 – Arrival time distribution associated with maltohexaose (a). The two species are thought to arise from a 
linear conformer and a V6 helical structure. After reduction (b) or deuteration (c), the conformational family reduces 
to a single, presumably disordered, species. Plot of drift time against m/z of a mixture of maltooligosaccharides 
dextran 5000 and amylose 2800 (maltooligosaccharides) showing singly, doubly and triply charged ion clouds (d). Red 
dots highlight significant ions. The trend line with a shorter drift time corresponds to amylase whereas the trend line 
with a longer drift time corresponds to dextran. Figure amended from Rashid et al.[33d] 
As might be expected, the mobility decreases with increasing DP or increasing oligomerization. 
Dextran, for the most part, exists as more extended conformers compared to the other equivalent DP 
polysaccharides, which is postulated to be as a result of the increased flexibility associated with the 
α1-6 bond. The TWCCSN2 did not linearly increase with increasing carbohydrate chain length, 
suggesting that the global conformation alters upon the successive addition of monomers. Nearly all 
the studied oligosaccharide ATDs consist of a single species, suggesting either mutaroation at the 
reducing terminus is minimal or anomers are inseparable under the conditions employed in this work. 
The only exception was the linear DP6 maltohexaose, which existed as two structures. However, only 
a single structure was observed after reduction and remarkably also after exchange of 18 of the 20 
exchangeable hydrogen atoms (within the hydroxyl groups) with deuterium (Figure 18). This result 
was attributed to perturbation of the hydrogen bonding network within the maltohexaose. 
Maltooligosaccharides have been reported to adopt rigid left-handed V6 helices with six sugar units 
per turn in solution. Formation of the necessary intra-helical hydrogen-bonding interactions between 
the reducing and non-reducing termini of this V6 helix is probably dependent on the reducing residue 
mutarotation isoform.
[91]
  The structure of the DP6 sugar is therefore likely to be at the interface 
between existing as a linear-like chain and the V6 helical structure. Pullulans (1-4-linked maltotriose 
connected by α1-6-linkages) were poorly separated from dextrans by IMS alone in agreement with 
solution-phase measurements where they are known to both adopt a similar random coil structure.
[92]
 
However, these structures are readily distinguished by their CID tandem mass spectra. These studies 
enabled the characterization of the enzymatic product resulting from the action of Mycobacterium 
tuberculosis GlgB, a potential anti-tuberculosis drug target, on maltooligosaccharides.
[33d]
 This 
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enzyme is known to transfer a portion of linear maltooligosaccharide onto the 6-OH position of the 
maltooligosaccharide backbone forming conformationally extended, branched structures. The same 
year, Huang et al. have reported the IMS separation and MS
2
 characterization of 3-aminoquinoline 
labelled isomeric oligogalacturonic acids (derived from pectin cell wall) in a mixture of 
oligosaccharides bearing various degrees of polymerization and levels of methyl esterification 
including certain methyl ester regioisomers.
[93]
  This suggests specific sites of methyl esterification 
affect the conformation more than others. However, there were instances where certain 
oligogalacturonic species were inseparable. In order to improve the separation of the isomeric 
galacturonic acid residues, the same group  reported on-line hydrophilic interaction chromatography 
(HILIC) prior to TWIMS.
[94]
  HILIC-TWIMS-MS
2
 allowed improved separation and discrimination 
of isomers. However, even using both HILIC and TWIMS separation, some isomers still remained 
extremely challenging to resolve. Estimations of the theoretical CCSN2 values highlighted that the 
current resolving power of TWIMS is insufficient to separate all isomeric methyl esterified 
oligogalacturonic acids completely. Other complex mixtures of oligosaccharides from a digest of 
sugar beet pectin have been subsequently studied, since they contain a large variety of both unknown 
structures and potential isomers. The combination of HILIC with TWIMS enabled simultaneous 
separation and characterization of isomeric beet rhamnogalacturonan I derived oligosaccharides based 
on the position of their glucuronic acid substituents. However, again, all isomers were not resolved 
using IMS alone due to the small differences in their 
TW
CCSN2 values. Nevertheless, some novel 
structural isomers were identified for the first time, which demonstrated that i) oligosaccharide 
structures from beet pectin digest were more complex than previously reported and ii) IMS is suitable 
for the discovery of new structures.  
  Finally, in the recent study of Plancot et al., IM-MS approaches were able to characterize 
arabinoxylan fragments obtained after endo-xylanase digestion of leaf extracts from two African plant 
species Eragrostis nindensis and Eragrostis tef.
[95]
 Multiple species were observed within the ATD 
suggesting the existence of structural isomers, confirmed by post-mobility tandem MS. Based on IM-
MS/MS experiments for a DP4 oligosaccharide, the isomer at the shorter drift times could be assigned 
to a branched arabinoxylan structure and the one at the longer drift times to the linear one (Figure 19). 
However, although the presence of isomers was evidenced by IMS, fragments having higher DP were 
unresolvable. 
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Figure 19 - Extracted ion mobility spectra of DP4 isomers (m/z 709). The insets show the tandem mass spectra 
associated with the drift times 5.70 and 6.18 ms. Figure taken from Plancot et al.[95] 
 
4.2 Glycopeptides/Glycoproteins 
The complexity of analysing glycoproteins and glycopeptides as a single, intact entity is 
increased due the isomeric nature of many of the carbohydrate moities. These factors have meant that 
MS techniques alone have often struggled to separate and therefore elucidate the different 
carbohydrate structures present and also define sites of glycosylation. With incorporation of IMS, 
analysis at the intact level has begun to emerge. The additional analytical dimension removes the 
requirement for lengthy deglycosylation and clean-up steps and in many cases has enabled 
simultaneous separation and identification. 
Use of collisional activation or collision induced unfolding (CIU) has been reported during 
IMS experiments due to its ability to induce a change in conformation, identifiable by IMS. Leary  
studied the effects of increasing the trap collision energy of a TWIMS instrument on the ATDs and 
mobility profiles of the small glycoprotein, MCP-1.
[96]
 Monocyte chemotactic protein 1 (MCP-1) is a 
chemo-attractant cytokine that recruits monocytes, dendritic cells, and memory T cells to the sites of 
inflammation. MCP-1 exists in equilibrium between monomer, dimer and higher oligomeric forms; 
MCP-1 monomer activates its cognate receptors, while oligomerization and glycosaminoglycan 
(GAG) binding has been proven essential for in vivo activity. IMS was used to structurally probe the 
MCP-1 monomer, the non-covalent MCP-1 dimer and a dimer analogue non-covalently bound to a 
semi-synthetic GAG (Figure 20). With increasing collision energy, longer arrival times were observed 
for both dimers, indicative of a more extended conformation. However, the monomer species 
remained compact at equivalent activation energies. Comparison of the bound and unbound dimers 
revealed that GAG binding stabilized the dimer complex towards dissociation, indicating that the 
interaction was across the two MCP-1 monomers. In a second paper by the same group, IMS was used 
to show different structural specificity for GAG binding to two different chemokine variations. The 
interactions of chemokines with GAG moieties are essential for regulating chemokine 
34 
 
oligomerization, cell migration and cellular recruitment and so an understanding of how the overall 
conformation is affected upon binding is sought after.
[97]
 CIU  has also been explored recently by the 
Ruotolo group for the larger, more complex system of a monoclonal antibody (mAb).
[98]
 Through use 
of collision energy ramps, mobility acquisition and heat map plots, the authors were able to 
demonstrate how the levels of glycosylation affect the unfolding of the mAb. 
 
Figure 20 - The arrival time distributions (ATD) associated with the 9+ MCP-1 dimer, isolated in the quadrupole 
region, at the labelled collision energies 3, 9, 15, 21 and 27 V (a). Binding of the semi-synthetic GAG analogue Arixta 
is observed to stabilize the dimer at higher collision energies, although results in a less compact conformation (b). 
Figure amended from Schenauer et al.[96] 
 
DTIMS  has also been applied by the Barran group to calculate 
DT
CCSHe values for beta-
defensins as free peptides and also for the glycoprotein equivalents; beta-defensins bound to heparin-
derived disaccharides (HDD).
[99]
 The authors observed a 5% increase in 
DT
CCSHe for the bound form 
signifying a strong interaction with a defined structure, further evidenced by the narrower ATD 
compared with the unbound form. Molecular modelling provided CCSHe values for comparison, 
although in all cases the 
DT
CCSHe values for bound HDD were less than expected. The conformations 
observed indicate that linear defensins may still access a functional fold. Similar techniques were 
applied to examine the interaction of metamorphic protein lymphotactin with fondaparinux. Upon 
titration of the carbohydrate with the protein, rapid aggregation was observed, which resulted in µm 
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assemblies.
[100]
 Mutated and truncated forms of the protein formed complexes of different 
stoichiometries with distinctive 
DT
CCSHe. These studies highlight how combining predictive 
methodologies such as molecular modelling with structural techniques such as IM can identify 
functional forms of proteins and interactions that can help to discern mode of action as well the 
formation of macromolecular structures. 
In addition to structural information, IMS enables separation of isomeric structures with the 
same m/z. Li et al. used a trend line separation method coupled with IMS to dramatically increase the 
signal-to-noise ratio of glycopeptides derived from a glycoprotein using trypsin digestion.
[101]
 One of 
the glycoproteins analysed has a significant carbohydrate content of approximately 45% across 5 N-
glycosylation sites. With such a high carbohydrate content, the likelihood of isomeric carbohydrates 
and hence isomeric or stereochemical glycopeptides is high. For some glycopeptides, multiple 
features in the ATD were observed for a single m/z emphasizing the ability of IMS to distinguish 
between isomeric glycopeptides.
[101]
 Separation of isomeric glycopeptides, differing only by the site 
of glycosylation, has also been reported by Creese and Cooper using FAIMS (Figure 21).
[102]
  
Combining FAIMS with routine bottom-up proteomic strategies has been shown to facilitate 
comprehensive mapping of the O-glycosylation profile of a glycoprotein, including identification of  
novel glycans and glycosylation sites.
[103]
 
 
Figure 21 – LCchromatogram highlighting lack of separation of two glycopeptides differing only by their site of 
glycosylation and the equivalent FAIMS trace where they are distinguishable. Figure taken from Creese.[102] . 
Analysis of bound glycoproteins and glycopeptides without substantial deglycosylation and/or 
digestion and/or purification is still relatively unexplored due to the challenges faced by MS 
techniques being unable to distinguish between the isomeric forms of the carbohydrates and their 
linked locations. However, incorporation of IMS has offered an additional dimension, allowing for the 
separation and identification of glycans without the need for removal from the peptide backbone. An 
advantageous side effect of these analyses is that structural characteristics at the intact level are 
observable and can offer hypotheses for functionality requirements.  
 
4.3 Glycolipids  
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Glycolipids are amphiphilic constituents of cell membranes containing a hydrophilic 
carbohydrate, varying from simple monosaccharides to complex polysaccharides, covalently bound to 
a hydrophobic lipid moiety. The growing interest in profiling cellular glycolipids has been motivated 
by the importance of the carbohydrate head groups in many biological processes including recognition 
events, adhesion and signalling pathways as well as their architectural role in cell membranes.
[104]
 
Among the glycolipid family, lipopolysaccharides (LPS) from bacterial origin may modulate the 
immune response and have been extensively used as components of antibacterial vaccines against a 
large variety of bacteria such as Heamophilus influenzae type b,
[105]
 Neisseria meningitidis type C
[106]
 
and Streptococcus pneumonia.
[107]
 Animals also contain the more complex glycosphingolipids, 
especially within the central nervous system, where the glycan part is linked to a ceramide moiety 
(composed of a sphingosine and a fatty acid).
[108]
  They are also reported to be vital for brain 
development, neuritogenesis, synaptic transmission and aging
[109]
 and also for many diseases such as 
Alzheimer‟s, Huntington‟s, Parkinson‟s, Niemann-Pick type C, Gaucher‟s and Guillain-Barré 
syndrome.
[110]
 Moreover, aberrant expressions of certain glycosphingolipids have been linked to 
several types of cancer, and hence, they have been frequently used as diagnostic biomarkers for 
different stages of cancer.
[111]
  Because of both their biological relevant functions and promising 
medical application, it seems essential to well characterize this family of glycoconjugates. However, 
analysis of glycolipids is not a simple task due to the inherent heterogeneity and complexity of their 
structure including the nature, number and position of the different monosaccharide residues, as well 
as the length, saturation and configuration of the carbon chains of lipid moieties.  
Li and co-workers were the first to report the combination of capillary electrophoresis (CE) 
and FAIMS-MS in order to analyse a mixture of O-deactylated LPS from Heamophilus influenzae 
strain 375.
[112]
 Although the potential of CE-FAIMS-MS to separate a complex mixture of LPS was 
demonstrated, FAIMS was solely used in this study to „filter out‟ the chemical background, thus 
enhancing detection limits. In 2007, Woods et al. studied the spatial distribution of cerebrosides 
species in rat brain section using MALDI-MS coupled to IMS.
[113]
 A few years later, Shvartsburg et 
al. described the separation of a variety of lipids using FAIMS. They have shown that monogalactosyl 
diacylglycerols (MGDG) and digalactosyl diacylglycerols (DGDG) fall on the same trend line within 
a 2D plot of compensation voltage and m/z and thus their MS information could be readily isolated 
from a complex mixture of lipids. The same year, Woods and co-workers reported the use of MALDI-
IM-TOF to separate a mixture of gangliosides, a well-studied class of glycosphingolipids, containing 
different proportions of negatively charged sialic acid (N-acetylneuraminic acid) as caesium adducts. 
Although two purified structural isomers GD1a and GD1b, which only differ by the position of the 
two sialic acids, generated identical MS spectra,  GD1a had a greater mobility compared to GD1b. 
IMS was able to separate, based on their degree of sialylation (i.e. GM1, GD1 and GT1), several 
gangliosides extracted from a mouse cerebrum, although the structural isomers GD1a and GD1b were 
poorly resolved in most cases.
[114]
 In a recent study, the group of Woods also reported the analysis of 
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similar isomers using IM-MS in negative ion mode circumventing the need for doping the sample 
with caesium salts, which would otherwise suppress the intensity of the studied glycolipids.
[115]
 Signal 
is also suppressed by the presence of phospatidylcholines and sphingomyelins, which both contain 
quaternary amines and so ionize very well in positive ion mode. However, even in negative ion mode 
the GD1 isomers were inseparable based upon their mobility.
[115]
 Notable trends were observed for the 
effect of lipid structure upon mobility for the negatively charged species akin to those mentioned for 
salt adducts. 
[116]
 Reducing the head size, increasing the radyl chain length, increasing degree of 
saturation, and increasing the number of sialic acids all increase the mobility.
[115]
  
 
5. Concluding Remarks and Future Outlook 
 
Over the past decade, the major advances in MS-based glycomic and glycoproteomic 
techniques, as well as chromatographic separation methods, have allowed identification of subtle 
structural changes associated with disease development and progression.
[117]
  However, so far, only a 
few reports have described the use of IM-MS to perform this task especially for glycomic 
applications, where additional separation technologies and structural information are urgently 
needed.
[10d, 10e, 62, 118]
 The resolving power of DTIMS,
[52a]
 TWIMS
[30]
 and FAIMS
[119]
 have improved 
significantly over a relatively short period of time, addressing initial issues of poor separation of 
certain isomeric carbohydrates. Also alternative forms of mobility separation are being developed, 
which show significant advances in resolving power. Kurulugama et al. developed a strategy termed 
overtone mobility spectrometry (OMS), which yields significantly improved resolving powers than 
the DTIMS from which it is derived. This instrument consists of a segmented drift tube, to which a 
uniform potential is applied across segment(s) at regular intervals forming a „sawtooth‟ gradient along 
the mobility cell. These phases are alternatively switched on and off and ions are only transmitted 
when their mobilities are in resonance with the phase change frequency. An interesting result is that 
overtones are observed.
[50a, 120]
 Cyclotron geometry segmented drift cell have also been developed,
[121]
 
where ion packets are propelled around the tube by changing the drift field at a frequency resonant 
with the ions drift time through each region of the cyclotron.
 
Ions out of resonance are not stable; 
therefore the cyclotron acts to trap ions of a given mobility. Increasing the number of cycles improves 
the resolving power (>300 for more than 10 cycles and >1000 for 100 cycles).
[121b, 121c]
 The downside 
of this is increased ion loss as the number of cycles is increased and a reduction of duty cycle, both of 
which reduce the sensitivity. Either way, improvement and optimization of this approach or 
development of novel technologies, will see the resolving power significantly improved with 
sufficient sensitivity and speed for analysis of biological glycans. Improvements associated with the 
speed, structure generation and usability of computational simulations (i.e. ab initio, semi-empirical 
or molecular dynamics) to generate theoretical candidate structures and CCSs will also facilitate 
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validation and characterization of dynamic structural/conformational information measured by IM-
MS
n
.  
Given that the structure, presence and proportion of specific glycan-biomarkers can change during 
the course of disease and these structures also vary from individual-to-individual, there will 
undoubtedly be benefits in developing glycan-based diagnostic tools for personalized medicine. As a 
result, rapid, sensitive and robust methods to characterize and identify biological glycans are required 
in order to carry out both diagnosis and prognosis, especially approaches that can detect diseases 
early. In fact, structural identification of aberrant glycosylation or specific structures associated with 
disease have already proved beneficial in the development of a large number of carbohydrate-based 
vaccines over the last 20 years such as anticancer,
[122]
 antibacterial
[123]
 or antiviral
[124]
 with many more 
still in development.
[125]
 There will also be the requirement to assess the quality of any isolated or 
synthesized carbohydrate-based medicines, further driving the requirement of robust analytical 
techniques. Initial applications of IM-MS to facilitate separation and identification of glycans,
[33c, 48a, 
50b, 56, 74, 126]
 glycosides,
[19b, 62, 114-115]
 polysaccharides,
[33f, 84, 86]
 glyco(peptides/proteins)
[102]
 and glycan-
based biomarkers
[10c-e, 62]
 are extremely promising, and further development and the recent 
commercialization of IMS technologies will inevitably increase its use within research and healthcare. 
The development of universal sequencing tools for carbohydrates with comparable speed and 
throughput to those used for nucleic acids and proteins remains a challenge, and IM-MS techniques 
are promising to be useful tools in this context. 
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